1011 China NT Pharma Group Co., Ltd.
China NT Pharma Group Co. (1011) news
China NT Pharma Group Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1011, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest China NT Pharma Group Co. news
We have not published a story on China NT Pharma Group Co. yet. When there is news, it will appear here.
Questions about China NT Pharma Group Co.
What is the ticker symbol of China NT Pharma Group Co.?
China NT Pharma Group Co., Ltd. trades under the ticker 1011 on HKEX.
Where is China NT Pharma Group Co. listed?
China NT Pharma Group Co., Ltd. is listed on HKEX.
Which country or territory is China NT Pharma Group Co. listed under?
Our directory records China NT Pharma Group Co., Ltd. under Hong Kong.
What does China NT Pharma Group Co. do?
Our directory classifies China NT Pharma Group Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of China NT Pharma Group Co.?
The ISIN recorded for China NT Pharma Group Co., Ltd. is KYG2114L1133.
Does aibio.space cover China NT Pharma Group Co.?
aibio.space lists China NT Pharma Group Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to China NT Pharma Group Co.?
Companies in our directory listed in the same country and business area as China NT Pharma Group Co.: Sirnaomics, SinoMab Bioscience, CPBIO Holding Company, Genscript Biotech, Sanai Health Industry Group Company, China Traditional Chinese Medicine Holdings Co..
Investor discussion: China NT Pharma Group Co.
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Share or debt issue: COMPLETION OF CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source
- Financings
Share or debt issue: CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE, APPOINTMENT OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source
- Financings
Share or debt issue: FURTHER DELAY IN DESPATCH OF CIRCULAR. Source
- Financings
Share or debt issue: DELAY IN DESPATCH OF CIRCULAR. Source
- Mergers
Transaction under the Listing Rules: UPDATE ON IMPLEMENTATION OF REMEDIAL ACTIONS AND KEY FINDINGS OF INTERNAL CONTROL REVIEW. Source
- Financings
Share or debt issue: CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source
- Mergers
Transaction under the Listing Rules: PAST NOTIFIABLE TRANSACTIONS AND CONNECTED TRANSACTIONS IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE AND LOAN AGREEMENTS AND DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR. Source
- Mergers
Transaction under the Listing Rules: PAST NOTIFIABLE TRANSACTIONS AND CONNECTED TRANSACTIONS IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE AND LOAN AGREEMENTS AND DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR. Source
- Mergers
Transaction under the Listing Rules: COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source
- Listings
Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source
- Listings
Trading status: TERMINATION OF THE SUBSCRIPTION AGREEMENTS IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND RESUMPTION OF TRADING. Source
- Listings
Trading status: TRADING HALT. Source
- Listings
Trading status: EXCHANGE NOTICE - TRADING HALT. Source
- Financings
Share or debt issue: ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE. Source
- Mergers
Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source
- Mergers
Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT - MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source
- Listings
Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source
- Listings
Trading status: INSIDE INFORMATION AND RESUMPTION OF TRADING. Source
- Listings
Trading status: TRADING HALT. Source
- Listings
Trading status: EXCHANGE NOTICE - TRADING HALT. Source
- Mergers
Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR. Source
- Mergers
Transaction under the Listing Rules: CLARIFICATION ANNOUNCEMENT - MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source
- Mergers
Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source
- Mergers
Transaction under the Listing Rules: COMPLETION OF CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source
- Mergers
Transaction under the Listing Rules: (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 17 FEBRUARY 2025; AND (2) GRANT OF WHITEWASH WAIVER. Source
- Mergers
Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT. Source
- Mergers
Transaction under the Listing Rules: DESPATCH OF THE CIRCULAR IN RELATION TO (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source
- Mergers
Transaction under the Listing Rules: (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source
- Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ANNOUNCEMENT ON (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; AND (2) APPLICATION FOR WHITEWASH WAIVER. Source
- Mergers
Transaction under the Listing Rules: PROFIT WARNING AND INSIDE INFORMATION ANNOUNCEMENT UPDATE ON FINANCIAL INFORMATION. Source
Press releases
- HKEXnews
- HKEXnews
Notification Letter and Request Form to Non-Registered Holder
- HKEXnews
Notification Letter and Reply Form to Registered Shareholder
- HKEXnews
- HKEXnews
APPOINTMENT OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
CHANGE OF (1) COMPANY SECRETARY, (2) AUTHORISED REPRESENTATIVE AND (3) PROCESS AGENT
- HKEXnews
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 28 AUGUST 2026
- HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
QUARTERLY UPDATES ON THE IMPLEMENTATION OF ACTION PLANS TO RESOLVE THE DISCLAIMER OF OPINION
- HKEXnews
- HKEXnews
- HKEXnews
UPDATE ON IMPLEMENTATION OF REMEDIAL ACTIONS AND KEY FINDINGS OF INTERNAL CONTROL REVIEW
- HKEXnews
Stock chart
Listing details
- Company
- China NT Pharma Group Co., Ltd.
- Ticker
- 1011
- Listing
- HKEX
- Country or territory
- Hong Kong
- Business scope
- Biotechnology
- ISIN
- KYG2114L1133
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio